Loading...
Loading...
TYRA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.1M |
| Gross Profit | -0.1M |
| Operating Expense | 28.6M |
| Operating I/L | -28.6M |
| Other Income/Expense | 4.6M |
| Interest Income | 4.6M |
| Pretax | -24.0M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -24.0M |
Tyra Biosciences, Inc. is a preclinical-stage biopharmaceutical company specializing in developing therapies to combat tumor resistance and improve outcomes for cancer patients. Its lead product candidate, TYRA-300, is a selective inhibitor of fibroblast growth factor receptor (FGFR)3 designed for the treatment of muscle invasive bladder cancer. The company also has programs targeting FGFR2-intrahepatic cholangiocarcinoma, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Additionally, Tyra Biosciences offers the SNAP platform, enabling rapid structural design through iterative molecular SNAPshots.
